Cellular Biomedicine Group Chooses Rockville, Maryland, R&D Cancer Immunotherapies Center
The Rockville campus will augment its global research and development capabilities and to support clinical trials in the United States centering around both its liquid tumor and solid tumor candidates.
According to company officials, the Rockville facility is strategically located in the heart of Maryland's life sciences center, on Medical Center Drive, an area commonly referred to as "DNA Alley."
The facility, when completed, will allow the development of new technology and preparation for clinical trials according to U.S. Food and Drug Administration (FDA) guidelines. The company intends for the facility to have a capacity to accommodate early phases of CBMG's clinical trials for its liquid and solid tumor candidates.
"This new site is poised to foster strategic partnership, new innovations, and support the continued development of CBMG's cell therapy based immune-oncology assets in the US that have showed promise in early proof-of-concept trials," said Tony (Bizuo) Liu, CEO for the Company.
Cellular Biomedicine Group, Inc. conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company's GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.
2023 Top States for Doing Business Meet the Needs of Site Selectors
2022 Top States for Doing Business Provide an Environment for Business Growth
Why the Southeast Is Winning EV Projects, With More on the Way
EV Impacts to Watch in 2023 and 2024
2023 Auto/Aero Site Guide
EV and Semiconductor Projects Stand Out in States Receiving Area Development’s 18th Annual Shovel Awards
Power-Intensive Site Selection
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers